Clinical trials: Essential Hypertension
Lower Leg Edema, Orthostatic Hypertension
Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients
Levacalm Tab. was approved in Jul 2013 by MFDS in South Korea. Levacalm Tab. is combination drug of Valsartan as an angiotensin II receptor blocker and Lercanidipine as a Calcium channel blocker.
- Trial name
- NCT02415192
- Testing
- Levacalm, Valsartan/amlodipine
- Where
- South Korea
- Volunteers
- 2,001 people
- Sponsor
- LG Life Sciences
Hypertension
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use…
- Trial name
- NCT00638911
- Volunteers
- 33,247 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Essential Hypertension, Hepatic Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers
- Trial name
- NCT01146938
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)
This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.
- Trial name
- NCT01431508
- Testing
- Losartan 50 mg / HCTZ 12.5 mg
- Volunteers
- 15 people
- Sponsor
- Organon and Co
Essential Hypertension
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension.
- Trial name
- ESAHOM (NCT02612298)
- Testing
- Arotinolol Hydrochloride, Metoprolol succinate sustained-release tablet
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Hypertension
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
This was a non-interventional, secondary use of data, retrospective, cohort study. The data extracted in this study was used as secondary use of collected patient information in the database, Japan Medical Data Survey (JAMDAS)…
- Trial name
- NCT06683768
- Where
- United States
- Volunteers
- 40,563 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696241
- Testing
- Azilsartan medoxomil and olmesartan, Olmesartan
- Where
- 85 sites in United States, Argentina and 1 more
- Volunteers
- 1,275 people
- Sponsor
- Takeda
Hypertension
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
- Trial name
- NCT00219154
- Testing
- aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,125 people
- Sponsor
- Novartis
Essential Hypertension
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
- Trial name
- NCT00856271
- Testing
- olmesartan medoxomil, losartan potassium
- Where
- 5 sites in China
- Volunteers
- 287 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension
Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects
The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.
- Trial name
- NCT01289899
- Testing
- BR-A-657
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.
- Trial name
- NCT00778921
- Testing
- Amlodipine 10 mg, Aliskiren 150, Amlodipine 300
- Where
- 7 sites in Argentina, Germany and 5 more
- Volunteers
- 847 people
- Sponsor
- Novartis
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
The objective of this clinical study is to evaluate the efficacy and safety by comparing the BR1010 treatment group to the fimasartan/amlodipine treatment group at Week 8 in patients with essential hypertension who do not…
- Trial name
- FINAL (NCT03991442)
- Testing
- Fimasartan/Amlodipine
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Hypertension
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension.
- Trial name
- NCT00367094
- Testing
- Benazepril plus hydrochlorothiazide
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Novartis
Essential Hypertension
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
The fixed combination of verapamil SR/trandolapril (Tarka®) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP)…
- Trial name
- NCT01127139
- Where
- 134 sites in Czechia
- Volunteers
- 3,828 people
- Sponsor
- Abbott
Essential Hypertension, Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06636877
- Testing
- BR1019, BR1019-2, BR1019-3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd